Background: Knowledge of quality-of-life after cytoreductive surgery is important to counsel patients with advanced-stage epithelial ovarian cancer prior to surgery. The aim of this study was to determine whether the use of the PlasmaJet Surgical device during cytoreductive surgery has an effect on the quality-of-life of patients with advanced epithelial ovarian cancer. Methods: Data included in this prospective observational study were derived from the PlaComOv study, in which patients with advanced epithelial ovarian cancer were randomly assigned to have cytoreductive surgery with or without adjuvant use of the PlasmaJet. Quality-of-life was measured before surgery and one, six, 12, and 24 months after surgery with three questionnaires: the EORTC QLQ-C30, QLQ-OV28, and EQ-5D-5L. Results: Between 2018 and 2020, 326 patients were enrolled in the trial. The overall response rate was high, with the lowest response rate at 24 months of 77%. At 6 months, quality-of-life was higher in the intervention group (95%CI 0.009; 0.081,p= 0.045). At 12 months, quality-of-life was higher in the intervention group with fewer symptoms of fatigue, appetite loss, and diarrhea (95%CI 0.6; 10,0,p= 0.027); similarly, patients in the intervention group reported a better body image (95%CI −14.2; −3.0,p= 0.003) and a higher score on the visual analog scale (95%CI 1.99; 11.15,p= 0.005). At 24 months postoperatively, no further difference was found between the two groups except for pain (95%CI −12.9; −0.8,p= 0.027) and body image (95%CI −13.808; −0.733,p= 0.029). A higher quality-of-life in the intervention group was partially explained by the mediator ‘surgery outcome’. Conclusions: This study demonstrated knowledge of patients’ quality-of-life until two years after cytoreductive surgery. The use of the PlasmaJet Surgical device during cytoreductive surgery leads to a higher quality-of-life than conventional surgery with electrocoagulation alone. Even after adjustment for the mediator of surgical outcome, a higher quality-of-life was seen in patients who had surgery with the use of the PlasmaJet device.
背景：了解肿瘤细胞减灭术后的生活质量，对于晚期上皮性卵巢癌患者术前咨询至关重要。本研究旨在探讨在肿瘤细胞减灭术中使用PlasmaJet外科设备是否会影响晚期上皮性卵巢癌患者的生活质量。方法：这项前瞻性观察性研究的数据来源于PlaComOv研究，该研究将晚期上皮性卵巢癌患者随机分组，分别接受辅助使用或不使用PlasmaJet的肿瘤细胞减灭术。通过三份问卷（EORTC QLQ-C30、QLQ-OV28和EQ-5D-5L）在术前及术后1、6、12和24个月评估生活质量。结果：2018年至2020年间，共有326名患者入组试验。总体应答率较高，24个月时的最低应答率为77%。在术后6个月，干预组的生活质量更高（95%CI 0.009; 0.081, p=0.045）。术后12个月，干预组的生活质量更高，且疲劳、食欲减退和腹泻症状更少（95%CI 0.6; 10.0, p=0.027）；同时，干预组患者报告了更好的身体意象（95%CI −14.2; −3.0, p=0.003）和更高的视觉模拟量表评分（95%CI 1.99; 11.15, p=0.005）。术后24个月，除疼痛（95%CI −12.9; −0.8, p=0.027）和身体意象（95%CI −13.808; −0.733, p=0.029）外，两组间未发现其他差异。干预组生活质量的提高部分可通过中介因素“手术结果”解释。结论：本研究揭示了患者肿瘤细胞减灭术后两年内的生活质量情况。在肿瘤细胞减灭术中使用PlasmaJet外科设备比仅使用电凝的传统手术能带来更高的生活质量。即使在调整手术结果这一中介因素后，使用PlasmaJet设备进行手术的患者仍表现出更高的生活质量。
肿瘤(癌症)患者之家